Global Pyruvate Kinase (PK) Deficiency Market, By Population (Infants, Children, Adults), Diagnosis (Bilirubin in the Blood, Complete Blood Count (CBC), Genetic Testing, Haptoglobin Blood Test, Osmotic Fragility, Pyruvate Kinase Activity, Stool Urobilinogen), Treatment (Blood Transfusion, Bone Marrow Transplantation, Splenectomy, Phototherapy, Folic Acid, Vitamin B, Iron Chelation (Key-Lay-Shun), Cholecystectomy, Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)), End User (Hospitals, Clinics, Research Organizations, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Pyruvate Kinase (PK) Deficiency Market
The pyruvate kinase (PK) deficiency market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 5.20% in the above-mentioned research forecast period. Increase in research and development and initiatives adopted by the market players are the factors for the pyruvate kinase (PK) deficiency market growth.
For instance,
- Agios Pharmaceuticals, Inc. had announced that the Mitapivat which is used for the treatment of the patients suffering from pyruvate kinase (PK) and are not been transfused with blood regularly has completed its phase III Activate trial and the results were reported that the drug was effective and safe to use. The company will file for the regulatory approval from the U.S. and EU in 2021 and will launch the product in 2022.
- In October 2019, Rocket Pharmaceuticals announced the clearance of IND for the gene therapy, RP-L301 which is used for the treatment of pyruvate kinase (PK) deficiency and will start the clinical trial phase.
Pyruvate kinase (PK) deficiency is an inherited and genetic disorder that affects the red blood cells (RBCs) which is responsible for carrying the oxygen to the body tissue. This condition is also known as hemolytic anemia which is characterized by the broke down of red blood cells prematurely resulting in decreased units of RBCs in body. The complications for the PK can be from mild to severe and sometimes the patient does not show any symptoms. The main cause for PK deficiency is autosomal recessive trait that is the child gets the disease from their family members.
Increase in pyruvate kinase (PK) deficiency in the population and high diagnostic rate are some of the driver factors for the pyruvate kinase (PK) deficiency market growth. For instance, there are more than 3.2-8.5 per million people suffering from PK deficiency among Western population. Increase in patient population suffering from the genetic disease is also one of the factors for the pyruvate kinase (PK) deficiency market growth. Nevertheless, huge financial burden coupled with lack of skilled professionals are the factors that hinder the growth of the pyruvate kinase (PK) deficiency market.
This pyruvate kinase (PK) deficiency market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the pyruvate kinase (PK) deficiency market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Pyruvate Kinase (PK) Deficiency Market Scope and Market Size
The pyruvate kinase (PK) deficiency market is segmented on the basis of population, diagnosis, treatment, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of population, the pyruvate kinase (PK) deficiency market is segmented into infants, children and adults.
- On the basis of diagnosis, the pyruvate kinase (PK) deficiency market is segmented into bilirubin in the blood, complete blood count (CBC), genetic testing, haptoglobin blood test, osmotic fragility, pyruvate kinase activity and stool urobilinogen.
- On the basis of treatment, the pyruvate kinase (PK) deficiency market is segmented into blood transfusion, bone marrow transplantation, splenectomy, phototherapy, folic acid, vitamin B, iron chelation (key-lay-shun), cholecystectomy and allogeneic hematopoietic stem cell transplantation (HSCT).
- On the basis of end user, the pyruvate kinase (PK) deficiency market is segmented to hospitals, clinics, research organizations and others.
- On the basis of distribution channel, the pyruvate kinase (PK) deficiency market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
Global Pyruvate Kinase (PK) Deficiency Market Country Level Analysis
Global pyruvate kinase (PK) deficiency market is analysed and market size information is provided by country, population, diagnosis, treatment, end user and distribution channel as referenced above.
The countries covered in the pyruvate kinase (PK) deficiency market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America is projected to dominate the pyruvate kinase (PK) deficiency market throughout the forecasted period owing to the global leaders in research and development activities and rise in patient assistance programs. Europe is considered as the second largest growing regional segment due to the high cases of pyruvate kinase (PK) deficiency disease. Asia-Pacific leads the market due to the developing healthcare facilities, large number of generic manufacturers and rise in government initiatives and specialist communities.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The pyruvate kinase (PK) deficiency market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to pyruvate kinase (PK) deficiency market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the pyruvate kinase (PK) deficiency market in the growth period.
Competitive Landscape and Global Pyruvate Kinase (PK) Deficiency Market Share Analysis
The pyruvate kinase (PK) deficiency market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global pyruvate kinase (PK) deficiency market.
The major players covered in the global pyruvate kinase (PK) deficiency market report are Kezar Life Sciences, Momenta Pharmaceuticals, Inc, Apellis Pharmaceuticals, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Vertice Pharma, Concord Biotech, Alkem Labs, Dr. Reddy’s Laboratories Ltd, Jubilant Life Sciences Ltd, Strides Pharma Science Limited, Mylan N.V., Novartis AG, Sanofi, Rigel Pharmaceuticals Inc, Incyte Corporation, Alexion Pharmaceuticals, Inc Rocket Pharmaceuticals, Ltd., Agios, Inc. among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-
